Open innovation

Transcription

Open innovation

Portfolio of Open Innovation Projects in Life
Science Sector and how to manage IP
Julia Roelofsen, Business development manager
E: [email protected] M: +31 6 5534 0746
Cleveland
-
Tokyo
-
Eindhoven
-
Leuven
-
London
-
Melbourne
AGENDA
WHAT & WHY OPEN INNOVATION
WHY OPEN INNOVATION IN LIFE SCIENCES
PROTFOLIO OF OPEN INNOVATION PROJECTS
PROCESS AND IP QUESTIONS AT EACH STAGE
EXAMPLES OF PROJECTS AND NEW TOOLS
Copyright 2013, NineSigma
www.ninesigma.com & www.ninesights.ninesigma.com2
HEALTHCARE INDUSTRY IS USING OPEN INNOVATION
“The complexity of the science and the scale
of the challenge mean that we cannot solve
these problems alone
We need to take a different approach - one
focused on partnership, collaboration and
openness”
Andrew Witty CEO GSK
Open innovation - the process of going outside your company’s four walls
(or your industry) and leveraging the discoveries of unobvious others TO
inspire new concepts, talents and technologies.
www.ninesigma.com & www.ninesights.ninesigma.com
Innovation was no longer controlled by the big
corporations
COMPANY SIZE
IN # EMPLOYEES
> 70% R&D
spend outside
large
organizations.
30% of R&D
spend is by
SME’s.
SOURCE: HENRY CHESBROUGH
Innovation is global R&D Intensity
€1.127.000.000.000 (1.127 trillion) each year
6.700.000 FTE
Sources of innovation have
grown dramatically – largely undetected
VISIBLE:
Patents, products in market,
publications…
SIGNALS OF CHANGE:
“Invisible”: competing technologies
from adjacencies, tacit knowledge,
capabilities, non published
experiments, expertise etc.
OPEN INNOVATION IS ABOUT
ACCESSING THE GLOBAL POOL OF
INNOVATION SYSTEMATICALLY:
Technologies and Players
Where does innovation come from
Your Innovation
Ecosystem
Small entrepreneurial
companies
Non-profits
Private Laboratories
Consultants
Large Corporates
Universities
EXISTING
NETWORKS
Business
Development
Other
Business
Units
Universities
Suppliers
National
Labs
Research
Center
Internal company
Retirees
University Technology
Transfer Offices
Others
NineSigma’s Global
Innovation Community
NineSigma
Affiliates
Individuals
Research
Institutes
The Challenges Driving Innovation
in Healthcare Sector
• Rising costs and falling margins
• Budget cutbacks
• Increased regulation
• Shorter patent life and generic competition
• The need to identify winners and fill product pipelines
• Speed to market and sustaining competitive advantage
• Emerging new business models and new entrants
Traditional ‘O I’ Approaches
In-Licensing
Not For Profit
Partnering
Open Labs
Consortia
Portals
Science Parks
10
INNOVATION OCCURRING OUTSIDE COMPANIES
Crowdsourcing
Crowdfunding
Mobile
Gamification
Empower the Patient
11
WHAT OI CAN BE USED FOR?
HOLY GRAIL
NEW MARKETS
NEW PRODUCTS
FILL IN GAPS
PURSUE PARALLEL PATHS
STAY AHEAD OF COMPETITION
FPO
NEW EQUIPMENT / COMPONENTS
NEW MATERIALS
PROCESS IMPROVEMENTS
NINESIGMA OPEN INNOVATION APPROACH
FRAME
FIND
SELECT
ACT
We frame the problem in a way that we will find ‘Unexpected Connection’ coming from
new region or industry. We advise selecting right partner and support companies to
act and engage into profitable innovation partnership.
HELPING FIND BREAKTHROUGH SOLUTIONS TO THE MOST
CRITICAL INNOVATION CHALLENGES
MATCHING OPEN INNOVATION TOOLS
FOR DIFFERENT NEEDS
MINIMIZE
RISK IN DECISION
MAKING BY
AQUIRING
KNOWLEDGE
TECHNOLOGY
LANDSCAPING
Translate the unknown
into the known and
anticipate threats.
SAVE TIME, DO
NOT RE-INVENT
THE WHEEL,
FIND SOLUTION
OR PARTNER
RFP (REQUEST FOR
PROPOSAL)
Find and apply
solutions and talent
already developed
elsewhere.
GENERATE ONGOING
FLOW OF SOLUTIONS,
IDEAS &
TECHNOLOGIES TO
FILL THE GAPS
NINESIGHTS
GALLERIES
Create visibility within
innovation community and
generate ongoing and
manageable flow of ideas
ENAGE WITH
INNOVATION
COMMUNITY &
POSITION AS
INNOVATION
LEADER
PRIZE BASED
COMPETITIONS
Get feasible results, such
as prototypes or design
concepts by working with
open innovation
community on prizebased competitions.
CASE STUDY: TECHNOLOGY LANDSCAPING
PROBIOTICS
OVERVIEW & CHALLENGES
• A business research team of a global Consumer Goods
Company wanted to understand the best, fastest point of entry
into the market for probiotic products that offered a specific
type of clinical benefit.
RESULTS
• NineSigma connected probiotic strains, patents, research
studies and validated clinical claims with companies. The
project was completed in 3 months.
• The Client conducted market and consumer insights research
in parallel to the Technology Landscaping project and made
recommendations to the Executive Team on the best way to
enter the market with the new product.
KEY TAKEAWAYS
• In developing a Technology Landscape,
NineSigma assembled and organized Clients’
internal knowledge, performed a global search,
found and vetted new clinical studies, crossreferenced and matched probiotic strains, patents,
products and research studies.
SUCCESS STORY: INNOVATION CONTEST
UNDER ARMOUR – NEW APPLICATIONS FOR
PERFORMANCE MONITORING FOR ATHLETES
HIGHLIGHTS
o New technologies and applications for Armour39 digital
wearable performance monitoring for athletes.
o Three phased challenge for proof of concept prototypes
o $35K prize for winners and co-development opportunity.
RESULTS
o Phase 1: 50 winning concepts receive developer kits.
o Phase 2: 15 semi-finalist invited to demonstrate POC.
o Phase 3: Grand prize winner receives $25K and $10K for
runner-up.
o Winners have the opportunity to collaborate with Under
Armour to commercialise their concepts.
KEY TAKEAWAYS
o
Innovation Contests are ideally suited to
accelerating product development through
the power of prize driven crowd sourcing.
SUCCESS STORY
GE HEALTHYMAGINATION BREAST CANCER
CHALLENGE
• Aspiration: To fight breast cancer.
• Challenge focused on mapping breast cancer pathways,
specifically to map the molecular/proteomic similarities between
breast cancer and other solid tumors.
• The challenge was receiving low results and the quantity and
quality of proposals needed to increase.
RESULTS
• NineSigma activated complex best practices, including outreach to
broad technical and non-technical audiences and a detailed
communications strategy to ensure challenge success.
• Over 500 proposals were received from 40 countries.
• Five winners selected: each received $100k seed award in addition
to support through mentorships and access to GE researchers and
industry thought leaders.
“It is often challenging for early stage research to
grab the attention of seed investors. The challenge
has shown us that there are a remarkable number
of breakthrough ideas out there that deserve
promotion, investment and incubation.”
KEY TAKEAWAYS
• The right access to technical communities is key. In
addition there are fundamentals that must be followed —
including activities before, during and after the challenge.
— Beth comstock
chief marketing officer
GRAND CHALLENGE
HEAD HEALTH CHALLENGE
• The GE NFL Head Health Grand Challenge is a $60 million
program to develop new solutions to advance understanding of
mild traumatic brain injury.
• The first $10 million Challenge invited proposals for scanning
technologies and biomarkers.
• A second $10 million Challenge with Under Armour launches Fall
2013 to find, fund, and develop new solutions to diagnose and
protect against traumatic brain injury
APPROACH
• With two challenge topics and a diverse judging panel, the prize
strategy was a critical component that had to be defined and
clearly communicated to a broad technical and consumer
audience
KEY TAKEAWAYS
• Translating each sponsor’s objective into an integrated topic and
prize strategy is critical to the success of the program
• A large scale, multi-year challenge can be defined, scoped, and
launched in a short period of time with executive support
SUCCESS STORY
PROTEIN STABILIZATION FOR AN EFFECTIVE AIDS
VACCINE
• Each day, 7,400 individuals worldwide are newly infected with HIV. This is
one of the greatest medical challenges of the 21st century. IAVI has
focused on AIDS vaccine development for over 10 years.
• Breakthrough discovery: Naturally occurring antibodies neutralize proteins
on the surface of the virus, “disarming” the HIV, but the protein is too
unstable to be effectively targeted and needed to be stabilized.
• IAVI previously ran a search which focused on vaccine specialists only and
didn’t receive anything of value.
RESULTS
• NineSigma identified the problem as a “protein stabilization” problem, and
more than 30 proposals were submitted from protein researchers globally.
• A result of the quality and volume of responses, IAVI was able to go back
to the Gates Foundation to secure more funding.
“NineSigma provided a number of promising new
approaches to protein stabilization that we had not
previously explored. We are confident that the
researchers they helped identify have much to
contribute to the development of an effective AIDS
vaccine.”
— WAYNE KOFF
CHIEF SCIENTIFIC OFFICER
OF IAVI
• The search identified two scientists who will receive a total of $875K
to develop solutions for generating stable protein complexes for use in
AIDS vaccines.
KEY TAKEAWAYS
• Defining the problem differently opened up a new audience.
• NineSigma didn’t go to the ‘usual suspects’ — as a result, a
wealth of valuable proposals were generated.
NineSights Innovation Portal
https://ninesights.ninesigma.com
EXAMPLE CLIENT GALLERY – PFIZER
Aim: Generate the
Flow of Ideas &
Technologies to
address technological
and R&D gaps
Welcome to NineSigma Online
Open Innovation Community
www.ninesights.ninesigma.com
PROVEN EXPERTISE IN PHARMA,
HEALTHCARE & MEDICAL PRODUCTS
PROJECT TYPES
ADJACENT INDUSTRIES
Antimicrobials or
infection control
• Antimicrobial Peptides for Oral Care
applications landscape
• Antifungal technology for aqueous solutions
• Antibody Purification Media for High pH
Cleaning
• Bacterial Spores Control Technologies
• Improving fungal cell permeability and/or
reducing efflux mechanisms
Safety, sampling &
efficacy testing
• Automated Biological Collection System
• Improved Cell Culture Systems for
Detecting Repeat Dosage Effects
• Skin Chemical Absorption Models and
Assay Technologies
• Sustaining Life In Vitro
Drug delivery
• Development Partners for Nasal
Formulations and Delivery Devices
• Encapsulation systems for probiotics
• Improving probiotics stability
• Microneedle liquid delivery system
Therapeutics / drug development /
pipeline
• Breakdown of Advanced Glycation
End-Products
• Metabolic modifiers via viral translocation
vectors
• Probiotic approaches to deliver important
oral care benefits
• Reducing urogenital itching and irritation
CHEMICALS & MATERIALS
CONSUMER PRODUCTS
HIGH TECH
WHAT ARE YOUR INNOVATION NEEDS ?
Business Models
Process
Analysed 129 Open Innovation
projects with healthcare
companies from 2010 to 2013
9%
26 %
•Mapped the companies ‘Needs’
• Sustained demand for technology and
process innovation
• Increasing demand for innovation for added
value products and new business models
Business
Efficiency
•Identified OPEN Innovation Trends
Technology
Added Value Products
49 %
Source: White Paper by Dr. Stephen Clulow
16 %
Business Value
NineSigma Cross-Industrial Experience in Technology
Scouting from ca. 3 000 projects
INNOVATION TRENDS IN HEALTHCARE INDUSTRY
healthcare companies Open
Process
Business Models
Innovation projects 2008 to 2013
Streamlining or adding new
capabilities,
internally or by partnering
Innovating revenue generation, moving
from sales of
drugs, diagnostics or devices
26
•Mapped the companies ‘Needs’
• Sustained demand for technology innovation.
• Increase in projects for late stage,
development and product launch.
• Upswing in Open Innovation for process
Business
Efficiency
•Identified OPEN Innovation Trends
improvement to manage costs and access
new capabilities through partnerships.
• Recent increase in demand for innovation for
added value products and new business models.
Source: White Paper by Dr. Stephen Clulow
9
%
%
Technology
Added Value Products
New technologies for all aspects of
healthcare
Additional product features or services that go
beyond expectations
49
%
16
Business Value
%
The Open Innovation Profiles
https://ninesights.ninesigma.com/web/siemens-gallery
MANAGING INTELLECTUAL PROPERTY AND
CONFIDENTIALITY: OI IP STRATEGY APPROACH
CROSS-DISCIPLINE OI COMMITTEE: R&D, MARKETING, BU, ENGINEERING & LEGAL
Preparation & Need
Assessment
Select strategic
Need with
Freedom to
Operate
Discovery
Evaluation
Agreement
Identify high
quality potential
solutions without
IP risk
Vet & select
solutions to meet
Need without IP
risk
Confirm chosen
solution & work
towards
agreeement
Select strategic need
SELECT OI VEHICLE
•Prior art search
•
•CHECK Current nda’s IN
PLACE
•Assess competitive
sensitivity
Define evaluation process
•Information reveal
KNOWN VS.
UNKNOWN
PARTNERS
IMPLEMENT
EVALUATION PROCESS
Define work plan
•
SELECTION
PROCESS
•Jda
•Material transfer
agreement
•
INTERNAL SEARCH
VS. OI
INTERMEDIARIES
•
INFORMATION
REVEAL PRE/POST
NDA
•
ANONYMOUS VS.
NAMED
•
CROSS FUNCTIONAL
EVALUATION TEAM
•Pre-NDA/CDA
ARTICULATE NEED
•Post-NDA/CDA
•
INFORMATION
REVEAL
Consider firewall
protection needs
•
SCOPE OF CRITERIA
•Project team selection
•
RESPONSE FORMAT
•
•
•
MULTI-FACETED
REVIEW
COLLABORATION
FRAMEWORK AND
WORK PLAN
IP & COMMERCIAL
GOALS
•Poc
•Confidentiality terms
•Nda
Negotiate ownership &
access
•Ip
•Licensing
•Supply agreement
•Publishing rights
•Transfer to 3rd party
•Acquisition
•…
Codevelopm
ent
NineSigma RFP
Need or challenge driven Innovation
request: Tacit knowledge (outside public
domain)
Solution Providers: thousands of people
who we suspect that might have a solution
Non Confidential: enables IP transfer and
partnership
60% Industry - Business / 40% Academia
Network effect: 30% proposals from
people we did not contact in the first place
KEY COMPONENTS OF A TECHNOLOGY SEARCH
1. DEFINING THE NEED
Title
Provide a short, compelling description of the need.
Description of the Need
What must the solution do for us
What is a ‘nice to have’
Background Information
To inform non-specialists
Get solutions from adjacent industries or domains
2. DETAILS OF HOW AND WHO
Possible Approaches
Broad scope
Can be omitted
Approaches not of interest
Project Phases
Help responders understand the project
Who should Respond
3. THE BUSINESS RELATIONSHIP AND FINANCIALS
Business Relationship
Timelines
financials
Where RFP goes? Who see it?
Targeted outreach to 10 000 – 15 000 people, who we suspect have the answer
• RFP IS LAUNCHED
• VIRAL NETWORKING
• RESPONSES RECEIVED
•
•
•
•
Distributed Globally via the Internet
Peer referrals, word of mouth, email forwarding
Weekly e-newsletter, website posting, RSS feeds
Affiliate programs, unsolicited 3rd party postings, redistributions
• Proactive customized searches and direct solicitation campaigns
How we reach people?
USA
Europe
Cleveland Leuven/Eindhoven
/London/ Paris
Japan South Korea
Tokyo Seoul
Australia
Melbourne
Who answers?
Network effect: 30% proposals from
people we did not contact in the first place.
40%
60%
Industry
Academia
Who answers?
Typically, 2/3 or more technologies submitted were unknown to the Client. In
some cases, the Clients, although highly knowledgeable in their field, knew
of none of the technologies because:
They came from businesses
who did not make their IP
publicly known.
or
From sources outside the
client’s core areas of expertise.
or
From geographically distant
sources for which the client
had no information.
EXPANDING YOUR REACH THROUGH
UNEXPECTED CONNECTIONS
PACKAGE LEAK
DETECTION
DISPENSER
TECHNOLOGY
MICROWAVE
EVEN HEATING
SENSORS
CONNECTIONS TO AND SOLUTIONS FROM ADJACENCIES
INNOVATION FROM ADJACENT INDUSTRIES
NOVEL BIOPHARMA MANUFACTURING SCALE PURIFICATION TECHNOLOGY
Biopharma Manufacturing is Expensive
Received 36 Proposals from 16 Countries
Completely new and unexpected technologies
Including companies <100km from our client
Client Rejected Promising Approaches
e.g, novel column chromatography with 10x
throughput, 5 x capacity and half the cost.
Chose Paradigm Shift Technologies
Using innovations in Material Sciences
Discussions with 5 companies
Deals with 2 For Purification Technology
INNOVATION FROM ADJACENT INDUSTRIES
ASSISTED LIVING PRODUCT OR DEVICE USING INTELLIGENT DEVICES
Assisted Living Services are Challenging
Received 40 Proposals from 15 Countries
Completely New and Unexpected Technologies
Adapted from other industry sectors:
Oil and Gas, Mechanical Engineering, Manufacturing
Supporting a Wide Range of Health Services
Heart, Blood, Injury, Neurodegeneration, Falls, and
Lifestyle Patterns such as Eating, Sleeping, Social
Client Chose Paradigm Shift Approaches
Force Sensors, Ultrasonic and IR Technologies with
Novel Applications in Healthcare
OPEN INNOVATION in Healthcare and Digital
Example Projects
•
•
Personal Health and Wellbeing Monitoring Technologies
• Video Analysis/Recognition of Human Activities
• New Imaging Modality for Bone and Cartilage
• Solutions for Accelerating Breast Cancer Diagnosis and Treatment
• Non-Contact Monitoring of Brain Activity
• Connecting Physical and Financial Health
• Automated Detection of a Fall
• High Precision 3-D Position Detection within the Human Body
Consumer Devices that Provide Personalized Advice for a Heart Healthy Lifestyle
• End User Applications for RFID Technology with New Sensing Capabilities
• New Technologies to Help Babies to Sleep Better
• Non-invasive Health & Wellness Monitoring for Individual Use
• In-home Technology for Bone Health Assessment
• Fast Analytical Measurement of Vitamin / Mineral Content
• Digital Identification and Behavior Recognition Technologies
• Low-Cost Video Display Module for Consumer Goods
• Methods for Diagnosis and Prognosis of Mild Traumatic Brain Injuries
• Toys and Games with Physiological or Psychological Sensing Systems
• Seeking Experts in Cardiovascular Health Risks
• Technology for Real-time Remote Video Transmission
MANAGING INTELLECTUAL PROPERTY AND
CONFIDENTIALITY THROUGHOUT THE PROCESS
REQUESTS CONTAIN NO CONFIDENTIAL OR
COMPETITIVE INFORMATION
• We have done more than 3000 projects so far
gaining enough experience on how to do it
ONLY AFTER SELECTION OF
POTENTIAL SOLUTION PROVIDERS,
CLIENT WILL ENGAGE AND ENTER INTO
A MORE DETAILED DISCUSSION:
REQUESTS CAN BE ISSUED ANONYMOUSLY
Confidentiality agreement
• Client decide to do so or not (90% are anonymous)
IP negotiation
Business terms
Solution Providers submit only
non-confidential proposal briefs
•Solution providers formally accept to submit non confidential
information
•NineSigma Program managers screen all proposals to make
sure of their non confidential nature
Client
Solution Provider
•We request in this stage any evidence that can support the
solution providers’ claim to be able to bring a compelling
solution. We do not ask the “how” at that stage
NINESIGMA is the firewall between the outside world (“the solution providers”) and the client. This way of working
Avoids IP contamination and protects both Solution Providers and client until the time the client decides to engage.
NineSigma firewall : Protecting the exchange of sensitive
information
Success NAP – Method to Assess Provider
NineSigma Report Out
Stage 1 Rank
Evaluation of Solution
Providers
Information Gathering
+
Final Evaluation
Success MAP - NineSigma’s Methodology for
Assessment and Acquisition
Three-stage process to maximize your Open Innovation opportunities
10 days
6 weeks
4 weeks
MOVING OPEN INNOVATION PROGRAM FORWARD
SCHEDULE A WORKING SESSION TO DEFINE THE NEEDS.
CONFIRM ALIGNMENT WITH NINESIGMA CAPABILITIES.
COLLABORATE TO OUTLINE PROGRAM SCOPE, TIMING AND INVESTMENT;
CUSTOMIZED TO YOUR SPECIFIC NEEDS.
Portfolio of the Open Innovation Projects in
Life Science Sector & IP management in OI
NineSigma – WHO WE ARE?: http://youtu.be/EEGufjzsSy8
Open for the innovation?
Welcome to learn more about OI
ANNEX 1: OPEN INNOVATION IN HEALTHCARE - SOLUTION SEARCH
WE WORK AT ALL STAGES OF THE DRUG
DISCOVERY AND DEVELOPMENT PROCESS
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
EXAMPLE PROJECTS: NEW PROJECT SELECTION
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
New Project Selection
• New Drug Candidates for Autoimmune Diseases (RA, IBD, etc.)
• New Target Molecules for Chronic Kidney Disease
• Obtaining Small-Molecule Inhibitors of Protein-Protein Interactions
• New Target Molecules for Activation of Autophagy
• New Target Molecules for Chronic Kidney Disease
• Drug Seeds for Inflammatory and Autoimmune Diseases
• Drug Seeds for Arterial Disease ( PAD or Aneurysms )
• Drug Seeds for Rheumatoid Arthritis
• Seeking Pharmaceutical Agents That Can Arrest or Reverse the Development of Atherosclerotic Plaques
• Solutions for Accelerating Breast Cancer Diagnosis and Treatment
EXAMPLE PROJECTS: R&D
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
R&D
• In Vivo Models Linking Autotaxin Inhibition to a Disease
• Engineering Stable Proteins
• Implant encapsulation methods to reduce inflammation
• High Performance Miniature Batteries for Medical Devices
• Low Cost Medium Format for Growing Microorganisms
• Partners for High-throughput Biochemical Characterizations
• Selective Nerve Blocking / Nerve-Activity Monitoring
• Introduction / Expression of Fluorescent Calcium Indicator into Nerve Tissue of Adult Animals
• Regulating Cholinergic Receptors
• Real Time Extended Depth of Focus Microscopic Imaging
• Improved Cell Culture Systems for Detecting Repeat Dosage Effects
• Acoustic Wave Technology for Biological Use
EXAMPLE PROJECTS: MANUFACTURING
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
MANUFACTURING
• A Smart Seal for Liquid Sample Vials
• Low Friction Technologies for Human Tissue Contact
• Seeking Alternative Protein Purification Techniques
• Homogenous Dry Powder Blending of Fine Drug Particles on Coarse Carrier Particles
• Antibody Purification Media for High pH Cleaning
• Filter Performance Analytical Method Needed
• Rapid Tool to Evaluate the Quality of Biologically Sourced Raw Materials
• The Long-term Storage System that Keeps Powders Dry
• On-line Detection of Bacterial Spore Formation in Fermenting Media
• On-line Monitoring of Glutamate Concentration in Fermentation Processes
• Manufacturing Technologies for Enteric Formulations
• Methods of Producing Immunoglobulin
• Contract Manufacturing for Wet Bead Milling / Micronization of Powder into Injectable Suspension
EXAMPLE PROJECTS: DELIVERY
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
DELIVERY
• Controlled Protein Release Technology
• Injectable, Long-lasting Depot for Drug Delivery Applications
• Miniature Drug Preparations That Resist Moisture and Humidity
• Improving the Onset of Action for Oral Medications
• Injectable Formulation Containing both Hydrophilic and Hydrophobic Drug Components
• Novel Phenylephrine Delivery Forms
• Development Partners for Nasal Formulations and Delivery Devices
• Bioavailability Boosting Technologies
• Improved Technology for Delivering Vaccines
• Near Term Novel Drug Delivery Methods
• Custom Time-Specific Delivery of Active Ingredients
• Materials that Expand, Swell, or Change Shapes in the Stomach
• Development Partners for Transdermal Peptide Delivery
• Smart Materials for Drug Delivery Systems
POST
LAUNCH
EXAMPLE PROJECTS: PACKAGING
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
PACKAGING
• Single Use Package for Tablets and Powders
• Package/Dispenser for High Viscosity Semi-Solid Material
• Fast Dissolving Unit Dose Oral Liquid Dispenser
• Packaging Compliance
• Sterility Assuring Ophthalmic Dispensing Technology
• Seeking Unit Dose Cream & Applicator Package and Services
• Open - Closed Interface Between Dry and Wet Environments
• Seeking Asian Packaging Companies Open for Technology Transfer into Overseas Markets (US, Europe,
Latin America)
• 2-System Gel Dispenser for Accurate Delivery of Small Gel Droplets
• Technology for Minimizing Friction between a Catheter Tube and Guide Wire
EXAMPLE PROJECTS: CLINICAL TESTING
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
CLINICAL
TESTING
POST
LAUNCH
CLINICAL TESTING
• Algorithms for Normalization of Clinical Data to Enable Advanced Predictive Healthcare Systems
• Non-invasive Health & Wellness Monitoring for Individual Use
• Analysis and Measurement of Airway Congestion
• Seeking Human Clinical Models for End Benefit Claims of Improved Energy and/or Reduced Fatigue
• Video Analysis/Recognition of Human Activities
• Real-Time Measurement of Neural Activity in the Brain Reward System
• Fast Non-invasive Diagnostics for Allergic Contact Dermatitis
• New Imaging Modality for Bone and Cartilage
• Non-Contact Monitoring of Brain Activity
• High Precision 3-D Position Detection within the Human Body
• Visualization and Monitoring for Non-Invasive Surgery
• Innovative Skin Analysis and Aging Forecast Device
EXAMPLE PROJECTS: POST LAUNCH
NEW
PROJECT
SELECTION
R&D
MANUFACTURE
DELIVERY
PACKAGING
POST LAUNCH
•Consumer Friendly Immune Status Monitor
•Home Diagnostics to Assess Vitamin and/or Mineral Deficiencies
•Monitoring "Measurable Benefit" for Ex-smokers
•Purchase Intent (Predictive) Modelling for Consumer Goods Concepts and Prototypes
•Human Motivation – Adoption and Long-term Formation of Positive Habits
•Ideation Challenge: Connecting Physical and Financial Health
•Consumer Devices that Provide Personalized Advice for a Heart Healthy Lifestyle
•Non-invasive Health & Wellness Monitoring for Individual Use
•Biosensing Technologies for Consumer Health Monitoring
•Measuring Physiological Indicators of Motivation for Healthy Habits
•Unobtrusive Sensors for Human Needs Recognition
•In-home Technology for Bone Health Assessment
•Accessible Diagnostics for Health Action
CLINICAL
TESTING
POST
LAUNCH
RECENT PROJECTS: VACCINES AND BIOPHARMA
Vaccines
• Improved Mycoplasma Vaccines
• Broad Spectrum Leptospira Vaccine
• Convenient Intra-Nasal Vaccine Delivery Device
• Looking for a Vaccine against Johne's Disease in Cattle
• Easy to Use Animal Vaccine Delivery Device
• Adjuvant for Transdermal or Transmucosal Vaccines
• Seeking Porcine Circovirus Vaccine
Biopharmaceuticals
• Development Partners for Transdermal Peptide Delivery
• Seeking Alternative Protein Purification Techniques
• Engineering Stable Proteins
• Antibody Purification Media for High pH Cleaning
• A Smart Seal for Liquid Sample Vials
• On-line Detection of Bacterial Spore Formation in Fermenting Media
• On-line Monitoring of Glutamate Concentration in Fermentation Processes
• Methods of Producing Immunoglobulin

Open innovation

Transcription

Similar documents

Success in Open Innovation

NineSigma`s Presentation

Strategic Open Innovation – Connecting with the Outside World to

Andy Zynga, Ph.D., CEO, NineSIgma

Mise en page 1 (Page 1)

Ilapak Italia Spa

bacterial culture

chimb.ca

openSAFETY – Packaging line

Packaging – just a bare necessity?

Fergie Saison de Rose

FestusManor Good News Gazette Update